Enhancing Cardiovascular Health in Southeastern United States for Underrepresented Racial and Ethnic Minorities With

Charles Muiruri1, Carrie Dombeck, Amy Corneli

  • 1Charles Muiruri, PhD, MPH, is a Health Services Researcher, Assistant Professor, Duke Department of Population Health Sciences and Duke Global Health Institute, Durham, North Carolina, USA. Carrie Dombeck, MA, is a Project Leader and Qualitative Research Analyst, Department of Population Health Sciences, Durham, North Carolina, USA. Amy Corneli, PhD, MPH, is a Social Scientist and Professor, Duke Department of Population Health Sciences and Duke Global Health Institute, Durham, North Carolina, USA. April C. Pettit, MD, MPH, is an Associate Professor of Medicine, Divisions of Infectious Diseases and Epidemiology, Vanderbilt University Medical Center, Nashville, Tennessee, USA. Nwora Lance Okeke, MD, MPH, is an Infectious Diseases Physician Scientist and Associate Professor, Duke Department of Medicine, Durham, North Carolina, USA. Chris T. Longenecker, MD, is a Non-invasive Cardiologist and Associate Professor, Division of Cardiology and Department of Global Health, University of Washington School of Medicine, Seattle, Washington, USA. Eric G. Meissner, MD, PhD, is an Infectious Diseases Physician Scientist and Associate Professor, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA. Sarah Gonzales, BA, is a Clinical Research Coordinator, Duke Department of Population Health Sciences, Duke University, Durham, North Carolina, USA. Shamea Gray, is a Community Advisory Member, Durham, North Carolina, USA. Joseph Vicini, BA, MDiv, is a Community Advisory Member, Nashville, Tennessee, USA. Morgan Lima, MSN, RN, AC, RN, is a Clinical Nurse, Vanderbilt University Medical Center, Nashville, Tennessee, USA. Mersedes Brown, MPH, is a Clinical Research Coordinator, Department of Population Health Sciences, Durham, North Carolina, USA. Mary C. Hill, is an undergraduate student, Duke University, Durham, North Carolina, USA. Joshua Kwawuvi, MPH, is a graduate student, Duke University, Durham, North Carolina, USA. Jules Iradukunda, MD, MSc, is a graduate student, Duke University, Durham, North Carolina, USA. Gerald S. Bloomfield, MD, MPH, is a Non-invasive Cardiologist and Associate Professor, Duke Division of Cardiology, Department of Medicine and Duke Global Health Institute, Duke University, Durham, North Carolina, USA.

Summary

People with HIV from minority groups face higher cardiovascular disease (CVD) risks. Interventions must address individual beliefs and systemic barriers for equitable care.

Related Concept Videos

Models of Health Promotion and Illness Prevention I01:25

Models of Health Promotion and Illness Prevention I

A model is a theoretical way to understand a concept or an idea. Models can overcome barriers to health regardless of diverse economic and cultural backgrounds. In addition, models make the task easier by providing different ways to approach complex issues. There are two major health promotion models: the health belief model and the health promotion model.
The health belief model (HBM) attempts to predict health-related behavior in specific belief patterns. According to the HBM, a person's...
2.2K
Models of Health Promotion and Illness Prevention II01:18

Models of Health Promotion and Illness Prevention II

The person's health status fluctuates continually, varying from being in good health to becoming ill and returning to being healthy. To understand the concept of illness prevention, there are two models. First, the health-illness continuum model is a graphic representation of an individual's wellness. It states that a person is considered healthy in the absence of physical disease and the presence of good emotional health.
The agent-host-environment model states that disease results...
1.7K
Stress Prevention and Stress Management Techniques VI01:30

Stress Prevention and Stress Management Techniques VI

Adopting a healthier lifestyle often requires overcoming significant challenges, but leveraging psychological, social, and cultural resources can facilitate meaningful change. Effective self-change hinges on understanding and applying key tools such as motivation and goal setting, which help sustain efforts toward long-term health benefits.
Motivation and Self-Determination
Motivation, the driving force behind behavior, plays a pivotal role at every stage of the change process. The research...
65
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
35
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
35
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
40